OliX-Pharmaceuticals-Announces-Results-from-Preclinical-Study-of-Hair-Loss-Therapeutic-Candidate
- Thread starter Tom4362
- Start date
Too advanced?
- Reaction score
- 3,659
When I'm old and bald, most likely.
- Reaction score
- 288
REEEEEEEEEE !
I wait for it too. Damn, lot of pretty intersting treatments are being developed these days.
- Reaction score
- 342
Hmm... where do you get that? The abstract says it inhibits the expression of hairloss related genes:Looks like it’s a 5-AR isoenzyme 1 and 2 inhibitor based on a special RNA platform, siRNA. I haven’t gone through all their patents to check if this is the one, but this is what I found quickly:
ASYMMETRIC siRNA FOR INHIBITING EXPRESSION OF MALE PATTERN HAIR LOSS TARGET GENE - OLIX PHARMACEUTICALS, INC.
<div p-id="p-0001">The present invention relates to an asymmetric siRNA which inhibits an expression of male pattern hair loss target genes and a use thereof and, more particularly, to an asymmetric swww.freepatentsonline.com
It’s supposed to be a finasteride/dutasteride type medication with primarily local effects.
The present invention relates to an asymmetric siRNA which inhibits an expression of male pattern hair loss target genes and a use thereof and, more particularly, to an asymmetric siRNA which inhibits an expression of 3-oxo-5-alpha-steroid-4-dehydrogenase 1 (SRD5A1) gene, 3-oxo-5-alpha-steroid-4-dehydrogenase 2 (SRD5A2) gene or androgen receptor (AR) gene, and a composition for prevention or treatment of hair loss comprising the asymmetric siRNA.
So, given it does this, what potential sides could this have if it goes systemic?
Yeah, but it also means that if you get systemic sides it's gonna take that much longer to have those subside.
But then they're claiming it degrades when it gets to blood. Let's hope it pulls that trick better than CB.
Last edited:
- Reaction score
- 732
My bad, just skimmed through it quick before I posted. It’s not 5-AR as far as I can see.
- Reaction score
- 614
I assume you mean ensure rather than prevent. Have a read:
https://www.sciencedirect.com/science/article/abs/pii/S0142961219308543
They use ultrasound activated liposomes to improve delivery to the target area. It's definitely a step but I prefer the OliX approach as they're also targeting the AR gene rather than SRD5A
waynakyo
Experienced Member
- Reaction score
- 465
“We are advancing a novel and potentially durable approach to treating hair loss with large market potential,” said Dong Ki Lee, Ph.D., founder and chief executive officer of OliX Pharmaceuticals. “Due to topical administration, our investigational therapy acts directly on the affected area and is rapidly degraded upon exposure to the blood, so it’s free from major systemic side effects such as sexual dysfunction caused by conventional hair loss therapeutics. Building on our experience evaluating RNAi therapeutics for skin diseases, we plan to initiate clinical trials of OLX104C by 2022.”
Do I believe them? Not sure. What if my d*** rapidly degrades at exposure.
Do I believe them? Not sure. What if my d*** rapidly degrades at exposure.
Our lives are already degraded, so who cares
I know this is a joke, but what is KY?
I was just kidding, as I am most of the time
It will be a very good treatment, but not a cure, yes. Not a single molecule will be a cure anyway, as you will have to apply it as long as you want hair.KY19382, also I dont think he was joking. People seem overly hyped. The drug has alot of potential, but it wont be a 'cure'.
They're currently doing series B funding. Transltation from latest press release on their website: (9th Feb)
"CK Biotech Inc. is a series in which 5 institutions including Korea Development Bank, Yozma Group Korea, Knet Investment Partners, Synergy Ivy Investment, and Biohub participate in two years of attracting Series A 6 billion in December 2018. By attracting 13.55 billion B, it laid the foundation for clinical trials on non-alcoholic steatohepatitis (NASH), obesity, baldness, and wounds through tissue regeneration.
CK Biotech is a company that pursues the development of innovative (first-in-class) new drugs. It was started in October 2016 by Professor Kang-yeol Choi of Yonsei University as a faculty establishment, and by controlling the fundamental principles of stem cell activation regulation, problems are solved. Instead of using a lot of cell therapy, they are developing treatments that regenerate damaged tissues in intractable diseases.
In particular , skin anti-aging, baldness, non-alcoholic steatohepatitis (NASH), using original technology that safely activates the Wnt/ b- catenin signaling pathway, which plays a key role in tissue regeneration in vivo . New drugs are being developed to fundamentally treat intractable diseases, such as metabolic diseases such as obesity and diabetes, which are unsatisfactory in medical demand, but lack of treatment or fundamental treatment development is limited.
CK Biotech's diseases of interest are incurable diseases in which the protein CXXC5 is significantly increased in patient tissues, and thus the wint signaling system is suppressed and the tissue regeneration function is lost. By discovering and improving substances that inhibit protein-protein binding with a protein called Dishevelled, which is a mechanism for inhibiting winter signal transmission by CXXC5, over the past 10 years, it shows therapeutic effects by restoring the regeneration function of biological tissues lost in patients. It is being developed as an innovative regenerative treatment.
In the case of low-molecular compound candidates being developed, by activating stem cells in vivo to restore the patient's tissue regeneration function (e.g., skin regeneration, liver protection and tissue regeneration in NASH, regeneration hair follicle formation), It was confirmed that it shows an excellent effect close to the fundamental treatment. Currently, preclinical trials have been completed for major candidates for development, and preparations for clinical trials are in progress. It aims to grow into a global renewable and innovative new drug company by completing phase 1 and 2 clinical trials for NASH and baldness treatment within the next few years."
재생성 조직재건 혁신신약 개발기업 “씨케이바이오텍” 시리즈B 유치
씨케이바이오텍 (CK Biotech Inc.)은 2018년 12월 시리즈A 60억 유치 2년만에, 한국산업은행, 요즈마그룹코리아, 케이넷투자파트너스, 시너지아이비투자, 바이오허브등5개 기관이 참여하는 시리즈B 135.5억을 유치하여 조직재생을 통한 비알콜성지방간염(NASH), 비만, 대머리, 상처 등에 대한 임상시험 발판을 마련했다. 씨케이바이오텍 은 혁신형(First-in-class)신약 개발을 추구하는 기업으로, 최강열 연세대학교 교수가 교원창업으로 2016년 10월 시작한 기업으로, 줄기세포 활성화조절에 대한...ckbiotech.co.kr
- Reaction score
- 614
Of course, my mistake I misread.
I'm always going to favour any therapy that tackles ARs directly over SRD5A though so I quite like this angle
- Reaction score
- 3,659
AR is the GOAT target. Since we're trying to compensate for our missing epi-testosterone which acts as both an AR antagonist and a 5-AR inhibitor, degrading AR comes closer to offering the whole-spectrum protection against androgens that our follicles are naturally lacking.
Wow, I'm grateful there are so many companies out there trying to find a cure.KY19382, also I dont think he was joking. People seem overly hyped. The drug has alot of potential, but it wont be a 'cure'.
They're currently doing series B funding. Transltation from latest press release on their website: (9th Feb)
"CK Biotech Inc. is a series in which 5 institutions including Korea Development Bank, Yozma Group Korea, Knet Investment Partners, Synergy Ivy Investment, and Biohub participate in two years of attracting Series A 6 billion in December 2018. By attracting 13.55 billion B, it laid the foundation for clinical trials on non-alcoholic steatohepatitis (NASH), obesity, baldness, and wounds through tissue regeneration.
CK Biotech is a company that pursues the development of innovative (first-in-class) new drugs. It was started in October 2016 by Professor Kang-yeol Choi of Yonsei University as a faculty establishment, and by controlling the fundamental principles of stem cell activation regulation, problems are solved. Instead of using a lot of cell therapy, they are developing treatments that regenerate damaged tissues in intractable diseases.
In particular , skin anti-aging, baldness, non-alcoholic steatohepatitis (NASH), using original technology that safely activates the Wnt/ b- catenin signaling pathway, which plays a key role in tissue regeneration in vivo . New drugs are being developed to fundamentally treat intractable diseases, such as metabolic diseases such as obesity and diabetes, which are unsatisfactory in medical demand, but lack of treatment or fundamental treatment development is limited.
CK Biotech's diseases of interest are incurable diseases in which the protein CXXC5 is significantly increased in patient tissues, and thus the wint signaling system is suppressed and the tissue regeneration function is lost. By discovering and improving substances that inhibit protein-protein binding with a protein called Dishevelled, which is a mechanism for inhibiting winter signal transmission by CXXC5, over the past 10 years, it shows therapeutic effects by restoring the regeneration function of biological tissues lost in patients. It is being developed as an innovative regenerative treatment.
In the case of low-molecular compound candidates being developed, by activating stem cells in vivo to restore the patient's tissue regeneration function (e.g., skin regeneration, liver protection and tissue regeneration in NASH, regeneration hair follicle formation), It was confirmed that it shows an excellent effect close to the fundamental treatment. Currently, preclinical trials have been completed for major candidates for development, and preparations for clinical trials are in progress. It aims to grow into a global renewable and innovative new drug company by completing phase 1 and 2 clinical trials for NASH and baldness treatment within the next few years."
재생성 조직재건 혁신신약 개발기업 “씨케이바이오텍” 시리즈B 유치
씨케이바이오텍 (CK Biotech Inc.)은 2018년 12월 시리즈A 60억 유치 2년만에, 한국산업은행, 요즈마그룹코리아, 케이넷투자파트너스, 시너지아이비투자, 바이오허브등5개 기관이 참여하는 시리즈B 135.5억을 유치하여 조직재생을 통한 비알콜성지방간염(NASH), 비만, 대머리, 상처 등에 대한 임상시험 발판을 마련했다. 씨케이바이오텍 은 혁신형(First-in-class)신약 개발을 추구하는 기업으로, 최강열 연세대학교 교수가 교원창업으로 2016년 10월 시작한 기업으로, 줄기세포 활성화조절에 대한...
- Reaction score
- 732
It’s a wild guess I know, but do you think it can regrow several norwoods combined with needling?
While I do firmly believe only hair cloning will be a true solution, I still continue to hope for a miracle where a topical might actually offer real regrowth.